Join us for a thought-provoking episode featuring Douglas Selinger, Founder and CEO of Plex Research, a visionary leader at the forefront of AI-driven drug discovery and biomedical innovation. In this conversation, we dive deep into how artificial intelligence is reshaping the life sciences landscape- from transforming molecular design to accelerating the journey of a therapy from early discovery to clinical impact.

We unpack how Douglas and his team apply advanced computational models, vast biological datasets, and predictive analytics to streamline R&D workflows for biotech and pharmaceutical organizations. The discussion explores the methodologies behind AI-powered platforms, the transition from algorithmic insights to tangible drug candidates, and the strategic decisions that enable companies to innovate faster and more efficiently.

You’ll hear real-world examples of how data-centric drug development is improving the precision of target identification, reducing costs, and opening new pathways for therapeutic breakthroughs. We also examine the evolving challenges of integrating AI within traditional scientific environments, the complexities of scaling technology across global pharma, and the opportunities emerging at the intersection of biology, computation, and entrepreneurship.

Douglas Selinger’s personal journey—from building scientific foundations to leading a tech-enabled life sciences company—offers a rare perspective on the mindset required to push boundaries in a rapidly advancing industry.

Episode Highlights:
A deep exploration of AI’s growing influence in drug discovery and development
Case-driven insights into how computational approaches are accelerating innovation
A look at the future of medicine shaped by algorithms, automation, and interdisciplinary collaboration

Whether you're a researcher, investor, or industry leader navigating the shift toward digital-first R&D, this episode provides actionable perspectives on how AI is redefining the future of healthcare. Get ready to understand how computational power meets scientific ambition—and how that convergence is transforming biotech, pharma, and patient outcomes worldwide.